Integer (NYSE:ITGR) Given Buy Rating at Benchmark

Benchmark reissued their buy rating on shares of Integer (NYSE:ITGR) in a research note published on Friday morning, Benzinga reports. They currently have a $130.00 price objective on the medical equipment provider’s stock.

A number of other research analysts have also issued reports on the company. CL King initiated coverage on Integer in a research report on Thursday, March 14th. They set a buy rating and a $137.00 price target for the company. Bank of America upgraded Integer from a neutral rating to a buy rating and boosted their price target for the stock from $105.00 to $135.00 in a research report on Monday, April 15th. Finally, KeyCorp boosted their price target on Integer from $123.00 to $139.00 and gave the stock an overweight rating in a research report on Tuesday, April 9th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Integer has an average rating of Moderate Buy and a consensus price target of $120.50.

Integer Trading Down 1.4 %

NYSE:ITGR opened at $109.58 on Friday. Integer has a 12-month low of $69.40 and a 12-month high of $123.99. The firm has a market capitalization of $3.67 billion, a P/E ratio of 37.92, a P/E/G ratio of 1.54 and a beta of 1.10. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.32 and a quick ratio of 1.71. The business has a 50 day simple moving average of $113.11 and a 200 day simple moving average of $99.78.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, April 25th. The medical equipment provider reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.02. Integer had a return on equity of 11.25% and a net margin of 6.01%. The business had revenue of $414.80 million during the quarter, compared to analyst estimates of $412.78 million. During the same quarter in the previous year, the firm posted $0.87 EPS. The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. Equities research analysts predict that Integer will post 5.31 EPS for the current year.

Institutional Trading of Integer

A number of hedge funds and other institutional investors have recently modified their holdings of ITGR. Wesbanco Bank Inc. purchased a new stake in shares of Integer during the first quarter valued at $1,904,000. Raymond James & Associates raised its position in Integer by 1.4% during the first quarter. Raymond James & Associates now owns 49,648 shares of the medical equipment provider’s stock valued at $5,793,000 after buying an additional 702 shares during the period. Norden Group LLC acquired a new position in Integer during the first quarter valued at $526,000. Azzad Asset Management Inc. ADV raised its position in Integer by 7.9% during the first quarter. Azzad Asset Management Inc. ADV now owns 7,772 shares of the medical equipment provider’s stock valued at $907,000 after buying an additional 566 shares during the period. Finally, Tributary Capital Management LLC raised its position in Integer by 1.2% during the first quarter. Tributary Capital Management LLC now owns 285,677 shares of the medical equipment provider’s stock valued at $33,333,000 after buying an additional 3,513 shares during the period. Institutional investors own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.